Brandywine Global Investment Management LLC Makes New $22.61 Million Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Brandywine Global Investment Management LLC acquired a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 185,976 shares of the biotechnology company’s stock, valued at approximately $22,613,000. Brandywine Global Investment Management LLC owned about 0.19% of Sarepta Therapeutics as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Manchester Capital Management LLC increased its stake in Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its position in shares of Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 156 shares during the last quarter. Sunbelt Securities Inc. raised its holdings in Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 232 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in Sarepta Therapeutics during the fourth quarter valued at approximately $36,000. Finally, Steward Partners Investment Advisory LLC grew its stake in Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 194 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on SRPT shares. Royal Bank of Canada dropped their price objective on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a research note on Thursday, February 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. HC Wainwright reaffirmed a “sell” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a report on Wednesday, March 19th. Finally, Scotiabank reduced their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a report on Thursday, March 20th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $167.41.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $70.41 on Monday. The firm has a market cap of $6.83 billion, a PE ratio of 56.33 and a beta of 0.79. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock’s fifty day moving average price is $102.66 and its two-hundred day moving average price is $115.90. Sarepta Therapeutics, Inc. has a one year low of $67.88 and a one year high of $173.25.

Insider Transactions at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 7.70% of the stock is currently owned by insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.